NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 69 filers reported holding NURIX THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,469,007 | +16.5% | 568,576 | +48.1% | 0.00% | 0.0% |
| Q2 2023 | $3,835,750 | +12.2% | 383,959 | -0.2% | 0.00% | 0.0% |
| Q1 2023 | $3,417,379 | -18.7% | 384,840 | +0.5% | 0.00% | 0.0% |
| Q4 2022 | $4,204,407 | -13.9% | 382,915 | +2.2% | 0.00% | -50.0% |
| Q3 2022 | $4,881,000 | +32.6% | 374,573 | +29.0% | 0.00% | +100.0% |
| Q2 2022 | $3,681,000 | -2.7% | 290,459 | +7.6% | 0.00% | 0.0% |
| Q1 2022 | $3,784,000 | -50.4% | 270,055 | +2.4% | 0.00% | -50.0% |
| Q4 2021 | $7,633,000 | -1.9% | 263,640 | +1.5% | 0.00% | -33.3% |
| Q3 2021 | $7,783,000 | +125.9% | 259,760 | +100.0% | 0.00% | +200.0% |
| Q2 2021 | $3,446,000 | -1.9% | 129,888 | +15.0% | 0.00% | 0.0% |
| Q1 2021 | $3,512,000 | +38.9% | 112,935 | +46.9% | 0.00% | 0.0% |
| Q4 2020 | $2,528,000 | +0.3% | 76,871 | +6.5% | 0.00% | 0.0% |
| Q3 2020 | $2,521,000 | – | 72,209 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |